Share on LinkedInShare on LinkedIn

ARTICLE · 05 MAY 2020

Patent Linkage In Singapore – Better To Be Safe Than Sorry

A recent decision of the Singapore High Court suggests that it is best for those seeking to register generic versions of pharmaceutical products to disclose all potentially relevant patents relating to those products.

SingaporeIntellectual Property

A recent decision of the Singapore High Court suggests that it is best for those seeking to register generic versions of pharmaceutical products to disclose all potentially relevant patents relating to those products, even if some or all of those patents do not cover the product as such.  Disclosure is a requirement under Singapore's patent linkage scheme.

Millennium only had process patents, so Zyfas did not declare them

  • The plaintiff ('Millennium') was the registered owner of various process patents relating to the anticancer drug "bortezomib".
  • The defendant ('Zyfas') applied to register a therapeutic product for a generic version of bortezomib with the Health Services Authority (HSA). This registration was subsequently allowed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from